ANI Pharmaceuticals (Nasdaq:ANIP) - Cotización, noticias y análisis

Resumen de acción ANIP

ANI Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla, fabrica y comercializa productos farmacéuticos de marca y genéricos de venta con receta en Estados Unidos y Canadá.

Acerca de la empresa

ANIP fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 58.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 37.42%

Ha pasado a ser rentable este año

Análisis de riesgos

Venta significativa por parte de personas con información privilegiada en los últimos 3 meses

Los accionistas han sido diluidos en el último año

Competidores de ANI Pharmaceuticals, Inc.

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$1.8b

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.2b

Pacira BioSciences

NasdaqGS:PCRX

US$1.2b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for ANI Pharmaceuticals
Historical stock prices
Current Share Price	US$67.36
52 Week High	US$70.81
52 Week Low	US$38.91
Beta	0.80
1 Month Change	-0.43%
3 Month Change	18.45%
1 Year Change	58.20%
3 Year Change	104.74%
5 Year Change	-4.52%
Change since IPO	969.21%

Noticias y actualizaciones recientes

Recent updates

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Rentabilidad de los accionistas

	ANIP	US Pharmaceuticals	Mercado US
7D	2.8%	2.3%	1.6%
1Y	58.2%	10.8%	25.1%

Rentabilidad vs. Industria: ANIP superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 9.5% el año pasado.

Rentabilidad vs. Mercado: ANIP superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.

Volatilidad de los precios

Is ANIP's price volatile compared to industry and market?
ANIP volatility
ANIP Average Weekly Movement	4.5%
Pharmaceuticals Industry Average Movement	10.2%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: ANIP no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ANIP (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	642	Nikhil Lalwani	www.anipharmaceuticals.com

ANI Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla, fabrica y comercializa productos farmacéuticos de marca y genéricos de venta con receta en Estados Unidos y Canadá. La empresa fabrica productos orales en dosis sólidas; semisólidos, líquidos y tópicos; sustancias controladas; y productos potentes, además de realizar el desarrollo y la fabricación por contrato de productos farmacéuticos. Comercializa sus productos a través de cadenas de farmacias minoristas, mayoristas, distribuidores y farmacias de venta por correo, organizaciones de compras colectivas, farmacias especializadas y hospitales.

Resumen de fundamentos de ANI Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de ANI Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de ANIP
Capitalización bursátil	US$1.41b
Beneficios(TTM)	US$15.48m
Ingresos (TTM)	US$486.82m

91.3x

Ratio precio-beneficio (PE)

2.9x

Ratio precio-ventas (PS)

¿Está ANIP sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ANIP
Ingresos	US$486.82m
Coste de los ingresos	US$181.51m
Beneficio bruto	US$305.30m
Otros gastos	US$289.83m
Beneficios	US$15.48m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 10, 2024

Beneficios por acción (BPA)	0.74
Margen bruto	62.71%
Margen de beneficio neto	3.18%
Ratio deuda/patrimonio	62.4%

¿Cómo se ha desempeñado ANIP a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ANIP

Recompensas

Análisis de riesgos

Competidores de ANI Pharmaceuticals, Inc.

NasdaqGM:HRMY

US$1.8b

NasdaqGS:COLL

US$1.2b

NasdaqGS:PCRX

US$1.2b

NasdaqGS:AMPH

US$2.1b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Recent updates

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$46.60

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

ANI Pharma launches generic Prochlorperazine maleate tablets